Bolt Biotherapeutics, Inc. (BOLT)
3.86
-0.04
(-1.03%)
USD |
NASDAQ |
Sep 08, 16:00
3.87
+0.01
(+0.26%)
After-Hours: 20:00
Bolt Biotherapeutics Debt to Equity Ratio : 1.711 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.711 |
| March 31, 2026 | 1.125 |
| December 31, 2025 | 0.8662 |
| September 30, 2025 | 0.7348 |
| June 30, 2025 | 0.6226 |
| March 31, 2025 | 0.5279 |
| December 31, 2024 | 0.4407 |
| September 30, 2024 | 0.2523 |
| June 30, 2024 | 0.22 |
| March 31, 2024 | 0.1879 |
| December 31, 2023 | 0.1793 |
| September 30, 2023 | 0.1626 |
| June 30, 2023 | 0.1511 |
| March 31, 2023 | 0.1398 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.1318 |
| September 30, 2022 | 0.1233 |
| June 30, 2022 | 0.1101 |
| March 31, 2022 | 0.1023 |
| December 31, 2021 | 0.0974 |
| September 30, 2021 | 0.0907 |
| June 30, 2021 | 0.0861 |
| March 31, 2021 | 0.0352 |
| December 31, 2020 | 103.44 |
| September 30, 2020 | -1.708 |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 0.3217 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.0127 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 40.34M |
| Total Liabilities (Quarterly) | 27.70M |
| Shareholders Equity (Quarterly) | 12.64M |
| Current Ratio | 2.614 |
| Net Debt Paydown Yield | 8.32% |